Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

141. Nebulised magnesium in asthma

Nebulised magnesium in asthma BestBets: Nebulised magnesium in asthma Nebulised magnesium in asthma Report By: Craig Ferguson - Clinical Research Fellow Search checked by Marten Howes - SpR Emergency Medicine Institution: Manchester Royal Infirmary Original author: Jonathan Costello Original institution: Royal Preston Hospital Date Submitted: 28th April 2003 Date Completed: 1st September 2004 Last Modified: 21st August 2006 Status: Green (complete) Three Part Question In [an adult with asthma (...) ] is [nebulised beta-agonist with nebulised magnesium sulphate better than nebulsed beta-agonist alone] at [improving airflow and reducing morbidity]? Clinical Scenario A known asthmatic patient is brought into the emergency department with signs consistent with acute asthma. Little improvement is noted with nebulised beta-agonist therapy. You wonder if adjunctive nebulised magnesium sulphate would provide any benefit. Search Strategy Medline 1966-05/04 using the Ovid interface. Repeated August 06 using Ovid

2004 BestBETS

142. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. (PubMed)

Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Magnesium is neuroprotective in animal models of stroke, and findings of small clinical pilot trials suggest potential benefit in people. We aimed to test whether intravenous magnesium sulphate, given within 12 h of stroke onset, reduces death or disability at 90 days.2589 patients were randomised within 12h of acute stroke to receive 16 mmol MgSO4 intravenously over 15 min and then 65 mmol (...) , and cortical stroke syndromes versus non-cortical strokes. Intention-to-treat and efficacy analyses were done.The efficacy dataset included 2386 patients. Primary outcome was not improved by magnesium (odds ratio 0.95, 95% CI 0.80-1.13, p=0.59). Mortality was slightly higher in the magnesium-treated group than in the placebo group (hazard ratio 1.18, 95% CI 0.97-1.42, p=0.098). Secondary outcomes did not show any treatment effect. Planned subgroup analyses showed benefit of magnesium in non-cortical

2004 Lancet

143. Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation

Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Coleman C I, Kalus J S, White C M, Spencer A P, Tsikouris J P, Chung J O, Kenyon K W, Ziska M, Kluger J, Reddy P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of ibutilide in the presence and absence of magnesium prophylaxis for the conversion of atrial fibrillation (AF). The mean dose of ibutilide was 2.2 (+/- 1) g. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

2004 NHS Economic Evaluation Database.

144. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials

Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

145. Magnesium sulphate versus diazepam for eclampsia. (PubMed)

Magnesium sulphate versus diazepam for eclampsia. Eclampsia, the occurrence of a convulsion in association with pre-eclampsia, remains a rare but serious complication of pregnancy. A number of different anticonvulsants are used to control eclamptic fits and to prevent further fits.The objective of this review was to assess the effects of magnesium sulphate compared with diazepam when used for the care of women with eclampsia. Magnesium sulphate is compared with phenytoin and with lytic cocktail (...) in other Cochrane reviews.We searched the Cochrane Pregnancy and Childbirth trials register (28 November 2002) and the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2002).Randomised trials comparing magnesium sulphate (intravenous or intramuscular administration) with diazepam for women with a clinical diagnosis of eclampsia.Both reviewers assessed and extracted data.Seven trials involving 1441 women are included. Most of the data are from trials of good quality

2003 Cochrane

146. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. (PubMed)

A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia. Nimodipine is a calcium-channel blocker with specific cerebral vasodilator activity. Our objective was to determine whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with severe preeclampsia.We conducted an unblinded, multicenter trial in which 1650 women with severe preeclampsia (...) were randomly assigned to receive either nimodipine (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional protocol) from enrollment until 24 hours post partum. High blood pressure was controlled with intravenous hydralazine as needed. The primary outcome measure was the development of eclampsia, as defined by a witnessed tonic-clonic seizure.Demographic and clinical characteristics were similar in the two groups. The women who received nimodipine were

2003 NEJM

147. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. (Full text)

Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Prenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very preterm infants.To determine the effectiveness of magnesium sulfate given for neuroprotection to women at risk of preterm birth before 30 weeks' gestation in preventing pediatric mortality and cerebral palsy.Randomized controlled trial at 16 tertiary hospitals in Australia and New Zealand with stratification (...) by center and multiple pregnancy. A total of 1062 women with fetuses younger than 30 weeks' gestation for whom birth was planned or expected within 24 hours were enrolled from February 1996 to September 2000 with follow-up of surviving children at a corrected age of 2 years.Women were randomly assigned to receive a loading infusion of 8 mL (4 g [16 mmol] of 0.5 g/mL of magnesium sulfate solution or isotonic sodium chloride solution [0.9%]) for 20 minutes followed by a maintenance infusion of 2 mL/h

2003 JAMA PubMed

148. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. (PubMed)

Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Intravenous magnesium can cause bronchodilation in treatment of severe asthma, however its effect by the nebulised route is uncertain. We aimed to assess the effectiveness of isotonic magnesium sulphate as an adjuvant to nebulised salbutamol in severe attacks of asthma.We enrolled 52 patients with severe exacerbations of asthma presenting (...) to the emergency departments at two hospitals in New Zealand. A severe exacerbation was defined as a forced expiratory volume at 1 s (FEV(1)) of less than 50% predicted 30 min after initial administration of 2.5 mg salbutamol via nebulisation. In this randomised double-blind placebo-controlled trial patients received 2.5 mg nebulised salbutamol mixed with either 2.5 mL isotonic magnesium sulphate or isotonic saline on three occasions at 30 min intervals. The primary outcome measure was FEV(1) at 90 min

2003 Lancet

149. Magnesium prophylaxis in cardiac surgery patients

Magnesium prophylaxis in cardiac surgery patients Magnesium prophylaxis in cardiac surgery patients Magnesium prophylaxis in cardiac surgery patients Higgins S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Higgins S. Magnesium prophylaxis in cardiac surgery patients. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2003: 30 Authors' objectives (...) This aim of this report was to assess whether, in patients undergoing cardiac surgery, prophylactic administration of magnesium reduces the incidence of adverse outcomes. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Heart Diseases /surgery; Magnesium; Thoracic Surgery /adverse effects Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton

2003 Health Technology Assessment (HTA) Database.

150. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. (PubMed)

Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. The benefits of supplemental administration of intravenous magnesium in patients with ST-elevation myocardial infarction (STEMI) are controversial. Despite promising results from work in animals and the ready availability of this simple, inexpensive treatment, conflicting results have been reported in clinical trials (...) . Our aim was to compare short-term mortality in patients with STEMI who received either intravenous magnesium sulphate or placebo.We did a randomised, double-blind trial in 6213 patients with acute STEMI who were assigned a 2 g intravenous bolus of magnesium sulphate administered over 15 min, followed by a 17 g infusion of magnesium sulphate over 24 h (n=3113), or matching placebo (n=3100). Our primary endpoint was 30-day all-cause mortality. At randomisation, patients were stratified

2002 Lancet

151. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. (PubMed)

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate.Eligible women (n=10141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical (...) uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. Follow up was until discharge from hospital after delivery. Analyses were by intention to treat.Follow-up data were available for 10,110 (99.7%) women, 9992 (99%) of whom received the allocated treatment. 1201 of 4999 (24%) women given magnesium sulphate reported side-effects

2002 Lancet

152. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials

The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials Jee S H, Miller E R, Guallar E, Singh V K, Appel L J, Klag M J Authors' objectives The objectives were to determine whether magnesium supplementation reduces blood-pressure (BP (...) ), to identify the dose-response relationship, and to determine trial characteristics associated with the greatest BP reductions. Searching MEDLINE was searched for articles published before May 2001 using the MeSH terms 'magnesium' and 'BP' in clinical trials. The authors also searched the reference lists from original and review articles and reviewed their own reference files. The search was restricted to articles published in English. Study selection Study designs of evaluations included in the review

2002 DARE.

153. Magnesium sulphate versus lytic cocktail for eclampsia. (PubMed)

Magnesium sulphate versus lytic cocktail for eclampsia. Eclampsia, the occurrence of a seizure in association with pre-eclampsia, is a rare but serious complication of pregnancy. A number of different anticonvulsants are used to control eclamptic fits and to prevent further seizures.The aim of this review was to compare the effects of magnesium sulphate with those of lytic cocktail when used for the care of women with eclampsia.The register of trials held by the Cochrane Pregnancy (...) and Childbirth Group was searched for relevant trials. The Cochrane Controlled Trials Register in The Cochrane Library Issue 2, 2000 was also searched.Randomised trials recruiting women with eclampsia, and comparing any use of magnesium sulphate with any use of lytic cocktail.Data were extracted from each report without any blinding of the results or of the treatments which women received.Two trials with 199 women were included in the review. These were both small and of average quality. Magnesium sulphate

2001 Cochrane

154. Nexium (Esomeprazole Magnesium) Delayed-Release Capsules

Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Drug Approval Package: Nexium (Esomeprazole Magnesium) NDA #21-153 & 21-154 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Company: AstraZeneca LP Application No.: 21-153 & 21-154 Approval Date: 2/20/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology

2001 FDA - Drug Approval Package

155. The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis

The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis Blackwell S C, Tomlinson M W, Berman S, Redman M E, Hassan S S, Berry S M, Hallak M, Sorokin Y, Cotton D B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of magnesium sulphate (MgSO4) seizure prophylaxis for pre-eclamptic women. MgSO4 therapy was given as a 6.g bolus followed by a 2 g/hour continuous infusion. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

2001 NHS Economic Evaluation Database.

156. Magnesium sulphate versus phenytoin for eclampsia. (PubMed)

Magnesium sulphate versus phenytoin for eclampsia. A number of different anticonvulsants are used to control eclamptic fits and to prevent further seizures.The objective of this review was to assess the effects of magnesium sulphate compared with phenytoin when used for the care of women with eclampsia. Magnesium sulphate is compared with diazepam and with lytic cocktail (in preparation) in other Cochrane reviews.We searched the Cochrane Pregnancy and Childbirth trials register and the Cochrane (...) Controlled Trials Register, Issue 3 1999.Randomised trials comparing magnesium sulphate (intravenous or intramuscular administration) with phenytoin for women with a clinical diagnosis of eclampsia.Trial quality was assessed and data extraction was done by two reviewers.Four trials involving 823 women were included. The trials were of good quality. Magnesium sulphate was associated with a substantial reduction in the recurrence of convulsions, when compared to phenytoin (relative risk 0.30, 95

2000 Cochrane

157. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. (PubMed)

Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Treatment of acute asthma is based on rapid reversal of bronchospasm and arresting airway inflammation. There is some evidence that intravenous magnesium can provide additional bronchodilation when given in conjunction with standard bronchodilating agents and corticosteroids. No systematic review of this literature has been completed on this topic.To examine the effect of additional intravenous magnesium (...) sulfate in patients with acute asthma managed in the emergency department.Randomised controlled trials were identified from the Cochrane Airways Review Group register. Bibliographies from included studies, known reviews and texts were searched. Primary authors and content experts were contacted.Randomised controlled trials or quasi-randomised trials were eligible for inclusion. Studies were included if patients presented with acute asthma and were treated with IV magnesium sulfate vs placebo.Data were

2000 Cochrane

158. The effects of magnesium supplementation on exercise performance

The effects of magnesium supplementation on exercise performance The effects of magnesium supplementation on exercise performance The effects of magnesium supplementation on exercise performance Newhouse I J, Finstad E W Authors' objectives To critique research that has addressed the effects of magnesium (Mg) supplements on exercise performance in athletes. Searching MEDLINE was searched from 1966 to June 1999. Other electronic sources searched were CINAHL, International Bibliographic (...) Information on Dietary Supplements, and SPORTDiscus. The reference lists of recent articles were checked. Study selection Study designs of evaluations included in the review The studies included were experimental studies using magnesium supplements with performance as a dependent variable. Specific interventions included in the review Studies of Mg supplements as a treatment were eligible. The doses used in the included studies ranged from 116 to 500 mg/day for 1 day to 3 months. Multivitamins or minerals

2000 DARE.

159. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials

Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials Rodrigo G, Rodrigo C, Burschtin O Authors' objectives To determine whether magnesium sulfate (MgSO4) provides an additive improvement in adults with acute asthma presenting to the emergency department (ED). The specific questions (...) . The search was restricted to English language publications. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Magnesium in the form of MgSO4, administered parenterally or by nebuliser. Participants included in the review Adult patients aged greater than 16 years, with acute asthma treated in the ED, were included. The mean age of participants was 38.3 years (plus or minus 13.4 years); 30

2000 DARE.

160. Higher-Dose Intravenous Magnesium Therapy for Children With Moderate to Severe Acute Asthma

Higher-Dose Intravenous Magnesium Therapy for Children With Moderate to Severe Acute Asthma PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2000 PedsCCM Evidence-Based Journal Club